Search Results
Aug 13, 2026, 08:15 ET Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory
More news about: Pulmatrix Inc.
Jul 10, 2026, 13:38 ET SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--PULM, SLP, OLN, and HUN
PULM) related to its merger with Eos SENOLYTIX, Inc. Upon closing of the proposed transaction, Pulmatrix shareholders are expected to own approximately
More news about: Monteverde & Associates PC
May 15, 2026, 08:20 ET Pulmatrix Announces First Quarter 2026 Financial Results
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory
More news about: Pulmatrix Inc.
Apr 21, 2026, 08:00 ET Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), today announced the closing of its previously announced private placement of Series B Convertible Preferred Stock ("Series B Preferred Stock") with
More news about: Pulmatrix Inc.
Mar 26, 2026, 08:00 ET Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix") and
More news about: Pulmatrix Inc.
Mar 02, 2026, 08:00 ET Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory
More news about: Pulmatrix Inc.
Feb 26, 2026, 08:05 ET Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory
More news about: Pulmatrix Inc.
Dec 22, 2025, 07:00 ET U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
2024;56(1):2406439.3 Montero IE, Hernandez-Gonzalez F, Sellares J. Epidemiology and prognosis of progressive pulmonary fibrosis: a literature review. Pulm Ther. 2025;11(3):347-363. doi:10.1007/s41030-025-00302-5.4 Cottin V, et al. The Burden of Progressive-Fibrosing Interstitial
More news about: Boehringer Ingelheim
Dec 18, 2025, 08:05 ET Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory
More news about: Pulmatrix Inc.
Oct 16, 2025, 08:05 ET Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory
More news about: Pulmatrix Inc.
Oct 08, 2025, 07:30 ET Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
patients with refractory chronic cough Poster Session: Late-Breaking Scientific Abstracts Posters: Guidelines, Diffuse Lung Disease, Pulm Vasc Disease and More Session Date & Time: October 21, 1:45-2:30pm CDT Location: Exhibit Hall Poster Area 6 Poster
More news about: Trevi Therapeutics, Inc.